Lens ~ exercise mimetic
MOTS-c exercise mimetic research: physical-capacity and performance findings
Exercise induces it; given to aged mice, it raised running capacity. The performance literature, tiled to source.
The short version
An exercise mimetic is a compound that reproduces some of the molecular changes exercise causes. The MOTS-c exercise mimetic idea earns that label two ways: exercise makes your muscles produce more MOTS-c, and when researchers injected extra MOTS-c into mice, the animals performed better. In aged mice it raised treadmill running capacity and grip strength. In a small human study, people with more MOTS-c in their blood were stronger in the lower body — though not necessarily fitter aerobically. Nobody has yet run a controlled trial giving MOTS-c to people to improve performance.
Why MOTS-c Is Framed as an Exercise Mimetic
The 2021 Nature Communications study is the anchor: it showed exercise induces endogenous MOTS-c expression in skeletal muscle and circulation, and that exogenous MOTS-c significantly enhanced physical performance in young, middle-aged, and old mice [2]. In aged animals (22-23.5 months), MOTS-c significantly increased treadmill running capacity (P=0.000002), grip strength, and gait [2]. That bidirectional relationship — exercise raises it, and it raises exercise capacity — is exactly the signature of an exercise-mimetic regulator.
A 2022 Physiological Reports study reinforced it: long-term physical activity raised skeletal-muscle MOTS-c, and a single MOTS-c dose improved acute exercise performance in mice [7]. The dual chronic-and-acute effect is unusual and is why the exercise-mimetic framing has held.
The term exercise mimetic is precise here, not promotional: it means a compound that reproduces some of the molecular adaptations of physical training. MOTS-c qualifies because it both responds to exercise and, when supplied, produces exercise-like gains in capacity in animals [2][7]. A 2024 study in diabetic sand rats added an intensity dimension — high- and moderate-intensity interval exercise changed mitochondrial MOTS-c levels in patterns that tracked metabolic markers, suggesting the endogenous response scales with training load [14].
The Human Performance Signal: Strength, Not VO2max
The clearest human data come from a preliminary study in which serum MOTS-c correlated positively with lower-body muscle strength but showed no relationship to VO2max [6]. The signal is strength-linked rather than aerobic-capacity-linked — a meaningful distinction for how the peptide might map onto human performance.
That is consistent with the muscle-centric mechanism: skeletal muscle is the primary target, and the 2024 CK2 work tied MOTS-c to muscle-specific effects on atrophy and glucose uptake [11]. Exercise interventions in humans also move the peptide — a 16-week program raised plasma MOTS-c in some participants — but with an ancestry interaction that cautions against a one-size answer [8].
Did MOTS-c improve your endurance or VO2max?
In mice, exogenous MOTS-c increased treadmill running capacity [2]. In a preliminary human study, serum MOTS-c correlated with lower-body strength but not with VO2max [6]. So the measured signal is strength-associated, not endurance-associated, and no human dosing trial has tested either outcome directly.
Capacity Across Age Groups
What makes the 2021 result notable is its breadth across the lifespan: enhanced physical capacity appeared in young, middle-aged, and old mice, positioning MOTS-c as a regulator of age-dependent physical decline and muscle homeostasis [2]. Endogenous muscle MOTS-c also rises with age in healthy men, tracking myofiber composition [5]. The age-spanning result matters because most candidate performance compounds are tested in young, healthy animals; a signal that survives into 22-month-old mice speaks to maintenance of capacity, not just peak enhancement [2].
The phrase to keep is physical capacity — treadmill running, grip strength, gait — measured in animals. These are not human performance outcomes, and the rodent doses used (15 mg/kg/day or 15 mg/kg three times weekly, intraperitoneal) are research figures, not human guidance [2]. The mechanism underwriting these gains is the same folate-cycle-to-AMPK axis covered on the underlying MOTS-c research: AMPK activation in skeletal muscle drives glucose uptake and the metabolic shift that supports sustained effort.
Muscle, Strength, and the Bodybuilding Interest in MOTS-c
Interest from strength and physique communities centers on the muscle findings. In mice, MOTS-c reduced myostatin (a protein that limits muscle growth) and muscle-atrophy signaling, and the 2024 CK2 study demonstrated prevention of skeletal-muscle atrophy and enhanced muscle glucose uptake [11]. Grip strength rose in aged mice given the peptide [2].
The honest caveat: no human muscle-growth trial has been completed, and the strength association in people is correlational [6][12]. The interest is real; the human efficacy data are not yet there.
What are the top peptides for muscle growth?
This digest covers only MOTS-c, so it does not rank peptides. In mice, MOTS-c reduced myostatin and atrophy signaling and enhanced grip strength [2][11], but no completed human muscle-growth trial exists, so it cannot be positioned against other compounds on human evidence [12].
From Mouse Capacity to Human Performance: the Translation Gap
The exercise-mimetic evidence is strong on one side and absent on the other, and the gap between them is the whole story. On the animal side: induced by exercise, enhancing treadmill capacity and grip strength across three age groups, acting acutely after a single dose, and underwritten by a defined muscle target [2][7][11]. On the human side: a strength correlation, an exercise-responsive plasma signal with an ancestry interaction, and no interventional performance trial at all [6][8].
Why the gap matters for performance specifically: rodent doses were 15 mg/kg given intraperitoneally, a route and scale that do not translate to people, and there is no validated human pharmacokinetics to bridge them — see MOTS-c half-life and pharmacokinetics [2][12]. A compound can be a clean exercise mimetic in mice and still be unproven in humans; MOTS-c is currently both. The capacity findings are real and reproducible in animals; the human performance question is open, not answered.